EFTA01100261Set 9
2016-02-2939p20,086w
being
successful in delivering therapeutic candidates. Importantly, for the lead clinical
program in Leber's disease, we see it as the right first target given that it is
relatively easier ... near-term. The most advanced program is for a eye disease called Leber congenital
amaurosis (LCA), which impacts a patient's retina and leads to blindness. This program is likely ... Editas is developing this technology for a
number of indications. The Editas pipeline includes Leber Congenital Amaurosis 10 (LCA10), genetic and
infectious diseases of the eye, gene editing
https://www.justice.gov/epstein/files/DataSet%209/EFTA01100261.pdf
EFTA00843868Set 9
2015-10-1139p13,287w
broader and more diffuse
clinical target, namely `behavioral disturbances in demented patients,' Dr. Paul Leber of the FDA
wrote. That label, he continued, "would also encompass a range of other ... were a big part of the market
targeted in Johnson & Johnson's business plan, Leber added, "Some [of these symptoms] ... might
even be construed by some as appropriate responses ... ethical question regarding the use of antipsychotic
EFTA00843886
medications for inappropriate behavioral control." Leber and the FDA appeared to have Johnson &
Johnson boxed in.
A year later, in August
https://www.justice.gov/epstein/files/DataSet%209/EFTA00843868.pdf